Literature DB >> 8714789

Cost analysis of dialysis treatments for end-stage renal disease (ESRD).

R Goeree1, J Manalich, P Grootendorst, M L Beecroft, D N Churchill.   

Abstract

The cost of alternative dialysis modalities for the treatment of end-stage renal disease (ESRD) was evaluated, using a societal viewpoint, in a regional nephrology program in south-western Ontario. The dialysis treatments compared were hospital hemodialysis, home hemodialysis, self-care hemodialysis, and continuous ambulatory peritoneal dialysis (CAPD). The participants were all patients treated by the same dialysis modality for the fiscal year April 1990 to March 1991. Fully allocated costs are expressed in 1993 Canadian dollars. The average costs per patient year were $88,585 for hospital hemodialysis, $55,593 for self-care hemodialysis, $44,790 for CAPD, and $32,570 for home hemodialysis. The dialysis treatment costs were $54,929 for hospital hemodialysis, $43,313 for self-care hemodialysis, $31,918 for CAPD, and $26,048 for home hemodialysis. These data quantify the magnitude of the differences between fully-allocated costs among the dialysis modalities in a regional nephrology program in Canada. The methodology used in this economic analysis can be applied to programs which differ in structure and scale. The breakdown of dialysis treatment costs into overhead, support department, personnel, supplies, and medication identifies potential areas for cost reduction strategies.

Entities:  

Mesh:

Year:  1995        PMID: 8714789

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  23 in total

1.  Nephrology in practice: a new series.

Authors:  A Ross Morton; Eric Wooltorton
Journal:  CMAJ       Date:  2002-01-22       Impact factor: 8.262

2.  Nephrology care in Canada.

Authors:  Keevin Bernstein; Claudio Rigatto
Journal:  CMAJ       Date:  2003-11-11       Impact factor: 8.262

Review 3.  Economic evaluation of dialysis therapies.

Authors:  Scott W Klarenbach; Marcello Tonelli; Betty Chui; Braden J Manns
Journal:  Nat Rev Nephrol       Date:  2014-08-26       Impact factor: 28.314

4.  Travel distance and home dialysis rates in the United States.

Authors:  Suma Prakash; Rick Coffin; Jesse Schold; Steven A Lewis; Douglas Gunzler; Susan Stark; Matthew Howard; Darlene Rodgers; Douglas Einstadter; Ashwini R Sehgal
Journal:  Perit Dial Int       Date:  2014 Jan-Feb       Impact factor: 1.756

5.  Cost-benefit model comparing two alternative immunisation programmes against serogroup C meningococcal disease: for Quebec residents aged 2 months to 20 years.

Authors:  Carol Rancourt; Jean-Pierre Grégoire; W Simons; Alain Dostie
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 6.  Identifying and slowing progressive chronic renal failure.

Authors:  B Curtis; B J Barrett; A Levin
Journal:  Can Fam Physician       Date:  2001-12       Impact factor: 3.275

7.  To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy.

Authors:  W F Clark; D N Churchill; L Forwell; G Macdonald; S Foster
Journal:  CMAJ       Date:  2000-01-25       Impact factor: 8.262

Review 8.  How to overcome barriers and establish a successful home HD program.

Authors:  Bessie A Young; Christopher Chan; Christopher Blagg; Robert Lockridge; Thomas Golper; Fred Finkelstein; Rachel Shaffer; Rajnish Mehrotra
Journal:  Clin J Am Soc Nephrol       Date:  2012-10-04       Impact factor: 8.237

9.  Reverse iontophoresis: a non-invasive technique for measuring blood urea level.

Authors:  Ismail Tuncer Degim; Sibel Ilbasmis; Rusen Dundaroz; Yusuf Oguz
Journal:  Pediatr Nephrol       Date:  2003-07-29       Impact factor: 3.714

Review 10.  Home dialysis as a first option: a new paradigm.

Authors:  Dimitrios G Oreopoulos; Elias Thodis; Ploumis Passadakis; Vassilis Vargemezis
Journal:  Int Urol Nephrol       Date:  2009-05-09       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.